bioAffinity Technologies Financial Results
bioAffinity Technologies reported its Q3 2026 financial results, highlighted by a 79% year-to-date increase in CyPath Lung testing revenue to $1.1 million. The company saw a 100% increase in test unit sales and an 89% increase in the number of ordering physicians compared to the prior year. Management noted continued momentum in commercialization and expansion of its government healthcare distribution network.
- Term
- Q3 2026
“Our third quarter results reflect the growing clinical adoption of CyPath® Lung as a vital tool for the early detection of lung cancer. With test unit sales doubling year-to-date and a significant increase in our physician base, we are seeing the direct impact of our commercial strategy and the clear need for noninvasive diagnostic solutions in the lung cancer care continuum.”
Maria Zannes, President and Chief Executive Officer